StockNews.com initiated coverage on shares of Reata Pharmaceuticals ( NASDAQ:RETA – Free Report ) in a research report released on Friday. The brokerage issued a sell rating on the stock. Other equities research analysts have also recently issued research reports about the stock. TD Cowen began coverage on shares of Reata Pharmaceuticals in a research report on Thursday, July 6th. They set an outperform rating and a $140.00 target price for the company. SVB Securities lowered Reata Pharmaceuticals from an outperform rating to a market perform rating in a report on Friday, July 28th.

https://www.dailypolitical.com/2023/09/09/reata-pharmaceuticals-nasdaqreta-coverage-initiated-by-analysts-at-stocknews-com.html

#dailypolitical